Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer.
[Genprex, Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

PhysIQ, Department of Defense, Duke University, Johns Hopkins and HJF Partner to Study COVID-19

PhysIQ Inc., Johns Hopkins University, Duke University and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. announced their collaboration to deploy physIQ’s platform to support a clinical trial to evaluate investigational products for early treatment and post-exposure prophylaxis of COVID-19.
[PhysIQ, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma, Inc. announced that the company has entered into a clinical trial collaboration and supply agreement with Bayer to evaluate ESSA’s lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Bayer’s androgen receptor inhibitor, darolutamide, in patients with metastatic castration-resistant prostate cancer
[ESSA Pharma, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Hope Bio’s Stem Cells to Be Used in Fight against Parkinson’s

Hope Biosciences Stem Cell Research Foundation received FDA authorization for a Phase II clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived MSCs in improving activities of daily living and quality of life in subjects with Parkinson’s Disease.
[Hope Biosciences Stem Cell Research Foundation]
Press Release
Bookmark

No account yet? Register

0
Share

City of Hope Opens Phase II Clinical Trial to Test If Intake of Mushroom-Powder Tablets Could Slow the Progression of Prostate Cancer

City of Hope announced that it is now recruiting patients for a Phase II clinical trial to investigate whether pills containing white button mushroom extract could regulate the immune system, affecting prostate-specific antigen levels to either remain stable or decline.
[City of Hope]
Press Release
Bookmark

No account yet? Register

0
Share

Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

Voyager Therapeutics, Inc. announced the FDA has removed its clinical hold on the company’s Investigational New Drug (IND) application for VY-HTT01, a gene therapy candidate for the treatment of Huntington’s disease, and confirmed that the company may proceed with its planned Phase I/II clinical trial.
[Voyager Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Ayala Pharmaceuticals Announces First Patient Dosed in Phase I Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with Relapsed/Refractory Multiple Myeloma

Ayala Pharmaceuticals, Inc. announced the dosing of the first patient in the ongoing Phase I clinical trial evaluating its potent investigational gamma secretase inhibitor, AL102, in combination with Novartis’ investigational anti-B-cell maturation antigen agent, WVT078, for the treatment of patients with relapsed and/or refractory multiple myeloma.
[Ayala Pharmaceuticals, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Reprogramming the Anti-tumor Immune Response via CRISPR Genetic and Epigenetic Editing

The basis for development, mechanism of action and outcomes from recently published Cas9-based clinical trial (genetic editing) and dCas9/Cas13-based pre-clinical (epigenetic editing) data are discussed.
[Molecular Therapy-Methods & Clinical Development]
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021). Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. Molecular Therapy - Methods & Clinical Development, 0(0). https://doi.org/10.1016/j.omtm.2021.04.009 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

+1
Share

Humacyte Announces Positive Long-Term Follow-Up Data from Phase II Vascular Access Trial

Humacyte, Inc. announced that five-year data from a Phase II clinical trial of patients receiving the human acellular vessels (HAV) for arteriovenous access in hemodialysis suggest the long-term durability and functional hemodialysis access of the HAV.
[Humacyte, Inc. (GlobeNewswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Hydrogels as Emerging Materials for Cornea Wound Healing

Scientists critically review in vitro, preclinical, as well as clinical trial studies related to corneal wound healing using hydrogels in the past 10 years, as this is considered as an emerging technology for corneal treatment.
[Small]
Khosravimelal, S., Mobaraki, M., Eftekhari, S., Ahearne, M., Seifalian, A. M., & Gholipourmalekabadi, M. (n.d.). Hydrogels as Emerging Materials for Cornea Wound Healing. Small, n/a(n/a), 2006335. https://doi.org/https://doi.org/10.1002/smll.202006335 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Monopteros Therapeutics Initiates Clinical Trial to Reprogram Regulatory T Cells in Solid Tumors

Monopteros Therapeutics, Inc. announced that it has dosed the first patient in its Phase I/Ib dose escalation and cohort expansion clinical trial. The trial aims to evaluate the safety, efficacy, and pharmacology of MPT-0118 and to demonstrate the reprogramming of regulatory T cells.
[Monopteros Therapeutics, Inc. (BusinessWire, Inc)]
Press Release
Bookmark

No account yet? Register

0
Share
Share